Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | LDHA | P00338 | 4/20 | 0.53 |
| ▸ | AR | P10275 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12297713 | 0.87 | RAB9A (0.75) | RAB9AMAPTLDHAARALDH1A1 | |
| SCHEMBL25917077 | 0.87 | MAPT (0.47) | RAB9AMAPTLDHAARALDH1A1 | |
| SCHEMBL25328215 | 0.87 | MAPT (0.54) | RAB9AMAPTALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL17900244 | 0.85 | LDHA (0.75) | LDHAALDH1A1L3MBTL1KDM4EPOLB | |
| SCHEMBL25916891 | 0.85 | RAB9A (0.55) | RAB9AMAPTLDHAALDH1A1L3MBTL1 | |
| SCHEMBL25917129 | 0.84 | KMT2A (0.53) | RAB9AMAPTLDHAALDH1A1SMN1; SMN2 | |
| SCHEMBL25916900 | 0.84 | RAB9A (0.54) | RAB9AMAPTLDHAALDH1A1L3MBTL1 | |
| SCHEMBL25917143 | 0.82 | RAB9A (0.48) | RAB9AMAPTLDHAALDH1A1L3MBTL1 | |
| SCHEMBL16273550 | 0.82 | RAB9A (0.53) | RAB9AMAPTLDHAARALDH1A1 | |
| SCHEMBL25328164 | 0.81 | RAB9A (0.58) | RAB9AMAPTLDHAARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372307-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372307-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023141262-A1 | BAX ACTIVATORS AND USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141262-A1 | BAX ACTIVATORS AND USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372307-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | BAK1, BCL2L1, BCL2A1 | RAB9A 2395/4885MAPT 4406/4885LDHA 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.